Filter articles using the following links

GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa

GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa

GenSight Biologics Provides 2021 Operations Update in the Context of COVID-19

GenSight Biologics Provides Update on Operations in the Context of COVID-19

GenSight Biologics receives MHRA approval to initiate Phase I/II PIONEER clinical trial of GS030 gene therapy in Retinitis Pigmentosa

GenSight Biologics receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa

GenSight Biologics receives Orphan Drug Designation and Advanced Therapy Medicinal Product classification in Europe for GS030 in Retinitis Pigmentosa